CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
about
Analysis of the genome to personalize therapy for melanomaMelanoma: oncogenic drivers and the immune systemHepatocellular carcinoma: From clinical practice to evidence-based treatment protocolsPathways and therapeutic targets in melanomaTargeted therapies in development for non-small cell lung cancerCombined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumorsElucidating distinct roles for NF1 in melanomagenesisAcquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3KHigh-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencingWhole exome sequence analysis of serous borderline tumors of the ovary.Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer TherapyUnderstanding the biology of melanoma and therapeutic implicationsRas/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Targeted therapy for melanoma: a primer.The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.Genotyping of cutaneous melanoma.Discovery of Sulfonamidebenzamides as Selective Apoptotic CHOP Pathway Activators of the Unfolded Protein Response.Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancerBeyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanomaPulmonary squamous cell carcinoma and sorafenibClinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma.Clinical detection and categorization of uncommon and concomitant mutations involving BRAF.In vitro and in vivo activity of a novel sorafenib derivative SC5005 against MRSA.Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategiesThe current state of targeted therapy in melanoma: this time it's personalRNA interference against SPARC promotes the growth of U-87MG human malignant glioma cells.Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNABlockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivoThyroid carcinoma-associated genetic mutations also occur in thyroid lymphomasSafety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study.CRAF R391W is a melanoma driver oncogeneTargeting the RAS pathway in melanoma.Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinibC-Raf is associated with disease progression and cell proliferation in a subset of melanomas.Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.Genetics and genomics of melanoma.Molecular-targeted therapy in malignant melanoma.NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.
P2860
Q24601008-C620D32A-1ED0-4A5A-816E-91CEE8E915FCQ26775598-238FE6E5-1A3D-4CE9-9689-C43CAC76B9B8Q26783881-921B36B1-EEB6-4795-9170-A8E175E5E073Q26865736-6D00107F-FB0B-431D-AA04-F7B844A86A5BQ27022852-FDDC8233-0FBB-41F4-A385-CE6CE2649EEFQ27349020-38C56C5D-E852-4E38-B088-280946FAA0F9Q27851952-45148CFB-A6BB-4474-8F07-28767DE36F79Q29614757-227EE55B-1B7C-4D46-9F7D-636E664E41EEQ30514084-5AD9AABE-24F4-4298-855D-882F020265B2Q33853093-372A78FD-437F-44DD-A84E-AFF4C7212FC1Q33859472-8C2BA092-074F-47A5-820D-C3CAF08ABA5AQ33978378-D36C2095-8C93-4BB7-820C-F6A7E52EBFA1Q34307356-6998EB23-3398-484A-8467-0561351F4A3AQ34540273-37C9A1D7-4BCF-4F5F-819A-3D50EDBBD87DQ34572036-D431810F-F6BB-4758-99A9-81AC217D6017Q34667738-C180FBED-2266-4CB6-87C9-C7E104044C62Q34701285-ED617B0E-C777-425C-8E1C-489E64D3042EQ34703562-8632D8BC-711A-4082-8AFB-EE96B3202E35Q34898560-CC059B16-DCE6-49FA-A065-700CBFA3DC62Q34998300-16149A45-EE78-4B89-9562-07E67A7F49AAQ35023498-BFC5702E-F989-45E4-97EC-C85ECB5087F7Q35693850-6FD758CD-F8D8-4A08-94B8-4C31EFEA2973Q35820044-F1BFA9A9-A168-4B6C-A1AE-D1AEDA37D372Q35836858-CAED898E-6B78-4AEA-89EE-BBFB3DBB16F4Q35859282-47DF76B2-C71E-44A5-B02C-80B5AA7789F3Q35878248-528F72C0-06E9-4595-B692-859E4A0644E4Q36126666-464E956C-5827-4523-9D6F-3ACD1339F044Q36128449-A9B180C0-6D26-43CB-98DB-F04A699CF8FDQ36162685-E510B666-6A6F-4EB8-9DF1-9C56446DC404Q36209975-EF443AE7-C249-4ABB-9C82-85F68EF62070Q36916295-60599B19-B12E-40F9-A6E2-40EF4FD8918EQ36980239-4E0D6EFC-D4C9-4C09-8CC1-39F4B3BB374AQ37137004-BB0C665C-6B96-4548-8471-2F2FF327F728Q37332008-1552E0E7-C514-4325-BE07-8B58EE0DEB75Q37389958-97B2C2DA-E740-4782-B3AD-49FEBA87C4C2Q37394504-80A0E983-5B05-4AB3-B455-E9650AE4D5C4Q37409032-2CABCAA2-CAC7-4804-A42B-8F4167996F90Q37483949-4E06F299-2B9C-4794-BC0E-6F471EEFF64FQ37689575-E0577943-1131-4A07-B959-76BB16F47D6CQ37727061-8072E464-34EE-43CE-897F-B9C3E9493261
P2860
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
@ast
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
@en
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
@nl
type
label
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
@ast
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
@en
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
@nl
prefLabel
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
@ast
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
@en
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
@nl
P2093
P2860
P3181
P356
P1433
P1476
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
@en
P2093
J Villanueva
K T Flaherty
P Van Belle
T K Nguyen
P2860
P2888
P3181
P356
10.1038/ONC.2008.362
P407
P577
2008-09-15T00:00:00Z
P5875
P6179
1024888641